Zacks Investment Research Downgrades Fluidigm (NASDAQ:FLDM) to Sell
According to Zacks, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California. “
NASDAQ:FLDM opened at $4.10 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.33 and a quick ratio of 1.87. The firm has a market cap of $261.61 million, a price-to-earnings ratio of -5.12 and a beta of 2.02. The company has a 50 day moving average price of $4.21 and a 200-day moving average price of $3.38. Fluidigm has a 1-year low of $1.17 and a 1-year high of $12.45.
A number of hedge funds and other institutional investors have recently modified their holdings of FLDM. Callan Capital LLC purchased a new stake in Fluidigm in the 1st quarter worth $25,000. Parallel Advisors LLC purchased a new stake in Fluidigm in the 1st quarter worth $26,000. Aperio Group LLC purchased a new stake in Fluidigm in the 1st quarter worth $27,000. Banque Cantonale Vaudoise purchased a new stake in Fluidigm in the 4th quarter worth $38,000. Finally, Arizona State Retirement System purchased a new stake in Fluidigm in the 1st quarter worth $41,000. 89.79% of the stock is owned by institutional investors.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.